Apnimed Prices Upsized IPO at $16 per Share, Raising $192 Million
Apnimed (APMD) priced its upsized initial public offering of 12 million shares at $16.00 each, raising approximately $192 million in gross proceeds. The biopharmaceutical company is focused on late-stage development and has also granted underwriters a 30-day option to purchase up to an additional 1.8 million shares. The IPO pricing reflects strong investor interest in the firm's pipeline of therapies targeting chronic diseases, particularly its lead candidate for obstructive sleep apnea. The offering size was increased from earlier estimates, indicating positive market reception and confidence in Apnimed’s growth potential.
Topics: biopharmaceutical financing ipo